# Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

> **NCT02422498** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 49 (actual)

## Conditions studied

- Locally Recurrent/Metastatic Triple Negative Breast Cancer

## Interventions

- **RADIATION:** external beam radiation therapy
- **DRUG:** cisplatin
- **PROCEDURE:** Biopsy of Target Tumor

## Key facts

- **NCT ID:** NCT02422498
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2015-04-14
- **Primary completion:** 2022-12-19
- **Final completion:** 2028-04-14
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02422498

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02422498, "Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02422498. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*